EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and Future

Hong-Beum Kim iD, Sang-Gon Park

Current Issues in Molecular Biology · 15.12.2025 · 47 (12) · 1044

DOI: 10.3390/cimb47121044 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 15.12.2025. Verfasst von Hong-Beum Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Premedical Course, Chosun University School of Medicine, 309 Pilmun-daero, Dong-gu, Gwangju 61452, Republic of Korea. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was supported by research fund from chosun university hospital, 2025., Chosun University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The limited efficacy of cytotoxic chemotherapy in the context of gastric cancer treatment is largely driven by profound molecular and biological heterogeneity. In contrast, the development of antibody-mediated therapies has ushered in a new era of precision oncology by enabling selective molecular targeting and immune modulation. This review includes a comprehensive overview of the evolution of antibody-based therapeutics in gastric cancer, highlighting early breakthroughs, subsequent setbacks, and recent advances that have reshaped the treatment landscape. We summarize the current standard regimens targeting HER2, VEGFR2, PD-1/PD-L1, and CLDN18.2 and examine pivotal clinical trials evaluating monoclonal antibodies directed against these pathways. We also discuss emerging therapeutic modalities, including next-generation antibody–drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. Trastuzumab first established HER2-targeted therapy in gastric cancer, but the failure of trastuzumab emtansine (T-DM1) led to a decade-long stagnation until the advent of trastuzumab deruxtecan (T-DXd), which demonstrated robust clinical activity and defined a new standard of care. While bevacizumab failed to improve survival, the anti-VEGFR2 antibody ramucirumab emerged as an effective second-line therapy. Immune checkpoint inhibitors, including nivolumab and pembrolizumab, have been incorporated into first-line treatment for PD-L1-positive disease based on landmark trials such as CheckMate 649 and KEYNOTE-811. More recently, the CLDN18.2-targeted antibody zolbetuximab has expanded therapeutic options for biomarker-selected patients. Concurrently, a diverse pipeline of immune-based strategies—such as TROP2-directed ADCs, bispecific antibodies, and CAR-T cell therapies—is undergoing active clinical development. Together, advances in biomarker-driven antibody therapeutics are accelerating personalized cancer care and improving clinical outcomes in patients with gastric cancer.

Schlagwörter

Stichwörter der Autor:innen

CLDN18.2HER2PD-1/PD-L1VEGFR2antibody-mediated therapyantibody–drug conjugates (ADCs)bispecific antibodiesgastric cancerimmune checkpoint inhibitors

Autor:innen und Institutionen

  • Department of Premedical Course, Chosun University School of Medicine, 309 Pilmun-daero, Dong-gu, Gwangju 61452, Republic of Korea.
  • Department of Internal Medicine, Hemato-Oncology, Chosun University Hospital, 365 Pilmun-daero, Dong-gu, Gwangju 61453, Republic of Korea.

ORCID-Profile: Hong-Beum Kim

Förderung

  • This study was supported by research fund from chosun university hospital, 2025.
  • Chosun University Hospital

Zitieren

APA

Kim, H. B., & Park, S. G. (2025). Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and Future. Current Issues in Molecular Biology, 47(12), 1044. https://doi.org/10.3390/cimb47121044

Vancouver

Kim HB, Park SG. Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and Future. Current Issues in Molecular Biology. 2025;47(12):1044. doi:10.3390/cimb47121044

BibTeX
@article{Kim2025,
  author = {Kim, Hong-Beum and Park, Sang-Gon},
  title = {Antibody-Mediated Therapy in Gastric Cancer: Past, Present, and Future},
  journal = {Current Issues in Molecular Biology},
  year = {2025},
  volume = {47},
  number = {12},
  pages = {1044},
  doi = {10.3390/cimb47121044}
}
Kostenlos starten →